These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 14729119)

  • 1. Neuroleptic-like effects of gamma-hydroxybutyrate: interactions with haloperidol and dizocilpine.
    Sevak RJ; France CP; Koek W
    Eur J Pharmacol; 2004 Jan; 483(2-3):289-93. PubMed ID: 14729119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cataleptic effects of gamma-hydroxybutyrate (GHB) and baclofen in mice: mediation by GABA(B) receptors, but differential enhancement by N-methyl-d-aspartate (NMDA) receptor antagonists.
    Koek W; France CP
    Psychopharmacology (Berl); 2008 Aug; 199(2):191-8. PubMed ID: 18446324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Streptozotocin-induced diabetes differentially modifies haloperidol- and gamma-hydroxybutyric acid (GHB)-induced catalepsy.
    Sevak RJ; Koek W; France CP
    Eur J Pharmacol; 2005 Jul; 517(1-2):64-7. PubMed ID: 15975572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic interactions between 'club drugs': gamma-hydroxybutyrate and phencyclidine enhance each other's discriminative stimulus effects.
    Koek W; Khanal M; France CP
    Behav Pharmacol; 2007 Dec; 18(8):807-10. PubMed ID: 17989519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine.
    Hauber W; Andersen R
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Nov; 348(5):486-90. PubMed ID: 8114947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State-dependent blockade of haloperidol-induced sensitization of catalepsy by MK-801.
    Schmidt WJ; Tzschentke TM; Kretschmer BD
    Eur J Neurosci; 1999 Sep; 11(9):3365-8. PubMed ID: 10510204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MK 801 reverses haloperidol-induced catalepsy from both striatal and extrastriatal sites in the rat brain.
    Kaur S; Ozer H; Starr M
    Eur J Pharmacol; 1997 Aug; 332(2):153-60. PubMed ID: 9286616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of excitatory amino acid mechanisms in gamma-hydroxybutyrate model of generalized absence seizures in rats.
    Banerjee PK; Snead OC
    Neuropharmacology; 1992 Oct; 31(10):1009-19. PubMed ID: 1436382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
    Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats.
    McAllister KH
    Eur J Pharmacol; 1996 Oct; 314(3):307-11. PubMed ID: 8957251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphine-induced catalepsy is augmented by NMDA receptor antagonists, but is partially attenuated by an AMPA receptor antagonist.
    Tzschentke TM; Schmidt WJ
    Eur J Pharmacol; 1996 Jan; 295(2-3):137-46. PubMed ID: 8720577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol.
    Yanahashi S; Hashimoto K; Hattori K; Yuasa S; Iyo M
    Brain Res; 2004 Jun; 1011(1):84-93. PubMed ID: 15140647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.
    Melo LL; Santos P; Medeiros P; Mello RO; Ferrari EA; Brandão ML; Maisonnette SS; Francisco A; Coimbra NC
    Brain Res; 2010 Aug; 1349():41-7. PubMed ID: 20558148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats.
    Schmidt WJ; Bubser M
    Pharmacol Biochem Behav; 1989 Mar; 32(3):621-3. PubMed ID: 2544900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats.
    Jelovac N; Sikiric P; Rucman R; Petek M; Marovic A; Perovic D; Seiwerth S; Mise S; Turkovic B; Dodig G; Miklic P; Buljat G; Prkacin I
    Eur J Pharmacol; 1999 Aug; 379(1):19-31. PubMed ID: 10499368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of adenosine and N-methyl-D-aspartate receptors in mediating haloperidol-induced gene expression and catalepsy.
    Chartoff EH; Ward RP; Dorsa DM
    J Pharmacol Exp Ther; 1999 Nov; 291(2):531-7. PubMed ID: 10525068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of GABAB receptors in the discriminative stimulus effects of gamma-hydroxybutyrate in rats: time course and antagonism studies.
    Carter LP; Flores LR; Wu H; Chen W; Unzeitig AW; Coop A; France CP
    J Pharmacol Exp Ther; 2003 May; 305(2):668-74. PubMed ID: 12606639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy.
    Zadow B; Schmidt WJ
    Naunyn Schmiedebergs Arch Pharmacol; 1994 Jan; 349(1):61-5. PubMed ID: 7908126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of antipsychotic treatments and D-serine supplementation on the electrophysiological activation of midbrain dopamine neurons induced by the noncompetitive NMDA antagonist MK 801.
    Bennett S; Gronier B
    Synapse; 2007 Aug; 61(8):679-88. PubMed ID: 17523181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists.
    Moore NA; Blackman A; Awere S; Leander JD
    Eur J Pharmacol; 1993 Jun; 237(1):1-7. PubMed ID: 8359205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.